Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
Dual GLP-1/GIP receptor activation providing broader metabolic benefits than conventional GLP-1 therapies.
However, tesofensine faces significant challenges - cardiovascular side effects (increased heart rate and blood pressure) raised safety concerns, FDA has not approved it despite promising efficacy data, development stalled after Phase 3 trials, currently available only through research chemical suppliers with questionable legality, and the stimulant-like mechanism creates dependency and tolerance risks not seen with GLP-1 agonists
Patient Educ Couns 99(6):926943
It's worth noting that crash diets or extreme calorie restriction may actually impair metabolic function, so gradual, sustainable changes are preferable
This represents an indirect effect mediated through metabolic improvement rather than a direct fertility-enhancing property of the medication itself
